Bostwick, D.G.; Wilk, M.M.; Bostwick, B.R.; Miller, N.; Rajaratnam, E.C.; Qian, J.; Rydesky, P.M.; Littrup, P.J.
First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial). Cancers 2025, 17, 2990.
https://doi.org/10.3390/cancers17182990
AMA Style
Bostwick DG, Wilk MM, Bostwick BR, Miller N, Rajaratnam EC, Qian J, Rydesky PM, Littrup PJ.
First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial). Cancers. 2025; 17(18):2990.
https://doi.org/10.3390/cancers17182990
Chicago/Turabian Style
Bostwick, David G., Melanie M. Wilk, Brian R. Bostwick, Norman Miller, Eugene C. Rajaratnam, Junqi Qian, Peter M. Rydesky, and Peter J. Littrup.
2025. "First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial)" Cancers 17, no. 18: 2990.
https://doi.org/10.3390/cancers17182990
APA Style
Bostwick, D. G., Wilk, M. M., Bostwick, B. R., Miller, N., Rajaratnam, E. C., Qian, J., Rydesky, P. M., & Littrup, P. J.
(2025). First-in-Human Phase II Clinical Trial of Multiplex IntraTumoral Immunotherapy (MITI) in Patients with Metastatic Solid Cancer (Abscopal 5001 Trial). Cancers, 17(18), 2990.
https://doi.org/10.3390/cancers17182990
